Additional file 10 of THOR is a targetable epigenetic biomarker with clinical implications in breast cancer

Additional file 10: Fig. S10. Demethylation of CpG sites across amplicons A2, A3, and A4 within THOR using the TETg7_MO plasmid. DNA sequencing electropherogram of amplicons A A2, B A3 and C A4, 48h post-transfection and after FACS sorting to select GFP-expressing cells, followed by bisulfite treatment. For each amplicon, are represented the DNA sequencing results for TET_MO (negative control) and TETg7_MO. The CpG positions within each amplicon are highlighted in blue. The methylated CpG cytosines remained intact in the negative controls (TET_MO), while the CpG sites indicated with the red arrows (TETg7_MO) were partially demethylated, converted into uracil and replaced by thymine following PCR, since it was detected an increase in thymine peaks in those sites.